专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0158869B1 CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES 审中-公开
标题翻译： CANNABINOID受体调节剂，其制备方法和CANNABINOID受体调节剂在治疗呼吸道疾病和非呼吸系统疾病中的应用
公开(公告)号：WO0158869B1
公开(公告)日：2002-02-21
申请号：PCT/US0104131
申请日：2001-02-08
申请人： SQUIBB BRISTOL MYERS CO , LEFTHERIS KATERINA , ZHAO RULIN , CHEN BANG CHI , KIENER PETER , WU HONG , PANDIT CHENNAGIRI R , WROBLESKI STEPHEN , CHEN PING , HYNES JOHN JR , LONGPHRE MALINDA , NORRIS DEREK J , SPERGEL STEVEN , TOKARSKI JOHN
发明人： LEFTHERIS KATERINA , ZHAO RULIN , CHEN BANG-CHI , KIENER PETER , WU HONG , PANDIT CHENNAGIRI R , WROBLESKI STEPHEN , CHEN PING , HYNES JOHN JR , LONGPHRE MALINDA , NORRIS DEREK J , SPERGEL STEVEN , TOKARSKI JOHN
IPC分类号： A61K31/40 , A61K31/404 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/421 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4353 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/551 , A61K45/00 , A61P11/00 , A61P11/06 , C07D207/337 , C07D207/40 , C07D207/416 , C07D209/08 , C07D209/42 , C07D231/14 , C07D231/56 , C07D233/90 , C07D257/04 , C07D263/32 , C07D271/06 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D471/04 , C07D471/08 , C07D471/10 , C07D498/04 , C07D498/06 , C07D207/34 , C07D401/14 , C07D407/12
CPC分类号： C07D207/416 , A61K31/40 , A61K31/415 , A61K31/44 , C07D209/42 , C07D231/14 , C07D231/56 , C07D233/90 , C07D257/04 , C07D263/32 , C07D271/06 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D471/08
摘要： Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R1-R6 are as defined in the specification, wherein R2 with R5 may form a ring, and/or two R4 groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R6 forming a ring with R3.
摘要翻译：公开了在化合物是大麻素受体调节剂的哺乳动物中用于治疗呼吸系统疾病的化合物的用途。用作治疗呼吸道和非呼吸性白细胞活化相关疾病的大麻素受体调节剂的化合物包括式（I）化合物，其中A和B为氮或碳，只提供A和B之一为氮; 和R 1 -R 6如说明书中所定义，其中R 2与R 5可以形成环，和/或两个R 4基团可以形成六元芳基或杂芳基环，任选地具有与R 3形成环的取代基R 6。

2. 发明申请

WO0208257A3 SIGLEC (SIALIC ACID-BINDING IG-RELATED LECTIN) POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译： SIGLEC（SIALIC ACID-BINDING IG相关LECTIN）多肽及其用途
公开(公告)号：WO0208257A3
公开(公告)日：2002-12-27
申请号：PCT/US0123082
申请日：2001-07-20
申请人： SQUIBB BRISTOL MYERS CO , LONGPHRE MALINDA , CHANG HAN , WHITNEY GENA
发明人： LONGPHRE MALINDA , CHANG HAN , WHITNEY GENA
IPC分类号： G01N33/50 , A61K38/00 , C07K14/47 , C07K14/705 , C07K16/18 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/02 , G01N33/15 , C07K16/28 , C12N15/62 , C12N15/63 , G01N33/68
CPC分类号： C07K14/705 , A61K38/00 , C07K2319/00
摘要： The present invention provides proteins, peptide fragments, nucleic acid molecules and fragments thereof, complementary sequences, allelic forms, homologues, antibodies and variants of SIGLEC-BMS sequences, which are new members of the Sialoadhesin subgroup having protein homology to CD33, and methods of using these molecules.
摘要翻译：本发明提供蛋白质，肽片段，核酸分子及其片段，互补序列，等位基因形式，同系物，抗体和SIGLEC-BMS序列的变体，其是与CD33具有蛋白质同源性的Sialoadhesin亚组的新成员，以及使用这些分子。

3. 发明申请

WO2002078618A3 METHODS OF MODULATING SURFACTANT PRODUCTION 审中-公开
公开(公告)号：WO2002078618A3
公开(公告)日：2002-10-10
申请号：PCT/US2002/002695
申请日：2002-01-30
申请人： BAYER CORPORATION , MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
发明人： MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
IPC分类号： A61K38/45
摘要： The present invention provides methods for modulating surfactant production using CDPDGS polypeptides, and agonists or antagonists that are capable of modulating CDPDGS activity. More particularly, the present invention encompasses the use of CDPDGS polypeptides, or agonist or antagonist polypeptides capable of modulating CDPDGS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the CDPDGS polypeptides, or agonist or antagonist polypeptides capable of modulating CDPDGS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.

4. 发明申请

WO2006002064A3 ANTIBODY INHIBITING STEM CELL FACTOR ACTIVITY AND USE FOR TREATMENT OF ASTHMA 审中-公开
标题翻译：抗体抑制干细胞因子活性及其在哮喘治疗中的应用
公开(公告)号：WO2006002064A3
公开(公告)日：2006-08-31
申请号：PCT/US2005021043
申请日：2005-06-14
申请人： AEROVANCE INC , NEBEN STEVEN , TAKEUCHI TOSHIHIKO , TOMKINSON ADRIAN , DELARIA KATHY , YAN KELLY , WONG TERESA , LONGPHRE MALINDA
发明人： NEBEN STEVEN , TAKEUCHI TOSHIHIKO , TOMKINSON ADRIAN , DELARIA KATHY , YAN KELLY , WONG TERESA , LONGPHRE MALINDA
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/564 , G01N33/566 , G01N33/6854 , G01N2800/122
摘要： The present invention provides human antibodies specific for stem cells factor that contain at least one CDR derived from a combinatorial antibody library. The invention also provides pharmaceutical compositions comprising the antibodies and methods of treating asthma. The invention further provides methods of detecting stem cell factor using the antibodies.
摘要翻译：本发明提供了特异于干细胞因子的人抗体，其含有至少一个来源于组合抗体文库的CDR。本发明还提供了包含该抗体的药物组合物和治疗哮喘的方法。本发明进一步提供了使用抗体检测干细胞因子的方法。

5. 发明申请

WO2005023860A2 MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS 审中-公开
标题翻译：修饰的IL-4突变蛋白受体拮抗剂
公开(公告)号：WO2005023860A2
公开(公告)日：2005-03-17
申请号：PCT/US2004/023310
申请日：2004-07-20
申请人： BAYER PHARMACEUTICALS CORPORATION , PAN, Clark , ROCZNIAK, Steve , GREVE, Jeffrey, Michael , YUNG, Stephanie, L. , LONGPHRE, Malinda , WONG, Teresa, Mo-fun , TOMKINSON, Adrian
发明人： PAN, Clark , ROCZNIAK, Steve , GREVE, Jeffrey, Michael , YUNG, Stephanie, L. , LONGPHRE, Malinda , WONG, Teresa, Mo-fun , TOMKINSON, Adrian
IPC分类号： C07K14/47
CPC分类号： A61K38/1709 , C07K14/5406 , C07K14/7155
摘要： This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
摘要翻译：本发明涉及包含与聚乙二醇偶联的IL-4突变蛋白受体拮抗剂的经修饰的IL-4突变蛋白受体拮抗剂。还提供了用于治疗目的的相关制剂和剂量及其施用方法。这些经修饰的IL-4突变蛋白受体拮抗剂，组合物和方法通过抑制IL-4和IL-13介导的气道高反应性和嗜酸性粒细胞增多来为患有呼吸病症例如哮喘的那些个体提供治疗选择。更具体地说，由于更长的血浆半衰期，这些拮抗剂相对于未修饰的IL-4RA具有增加的作用持续时间。

6. 发明申请

WO2002095008A3 METHODS OF MODULATING SURFACTANT PHOSPHOLIPID PRODUCTION 审中-公开
公开(公告)号：WO2002095008A3
公开(公告)日：2002-11-28
申请号：PCT/US2002/002728
申请日：2002-01-30
申请人： BAYER CORPORATION , MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
发明人： MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
IPC分类号： C12N15/12
摘要： The present invention provides methods for modulating surfactant production using SREBP/ADD-1 polypeptides, and agonists or antagonists that are capable of modulating SREBP/ADD-1 activity. More particularly, the present invention encompasses the use of SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.

7. 发明申请

WO2006036878A3 INTERLEUKIN-9 AND INTERLEUKIN-4 CHIMERIC ANTAGONIST MUTEINS AND METHODS OF USING SAME 审中-公开
标题翻译：白细胞介素-9和白细胞介素-4重要的拮抗剂和其使用方法
公开(公告)号：WO2006036878A3
公开(公告)日：2009-04-09
申请号：PCT/US2005034388
申请日：2005-09-21
申请人： AEROVANCE INC , BOISVERT DAVID C , LONGPHRE MALINDA , WONG TERESA M , ZAREMBA SYDNEY M
发明人： BOISVERT DAVID C , LONGPHRE MALINDA , WONG TERESA M , ZAREMBA SYDNEY M
IPC分类号： C12N15/00 , A61K39/395 , C12N5/00
CPC分类号： C07K14/54
摘要： Chimeric polypeptide antagonists that include an interleukin-4 (IL-4) mutein linked to an interleukin-9 (IL-9) mutein are provided, as are polynucleotides encoding the IL-4 and IL9 chimeric mutein antagonists. Also provided are methods of using the chimeric mutein antagonists and encoding polypeptides to reduce or inhibit the responsiveness of a cell to a cytokine such as IL-4, IL-9 and/or interleukin-13. Methods using the compositions to treat disorders such as pulmonary disorders (e.g., asthma) also are provided.
摘要翻译：提供了包含与白细胞介素-9（IL-9）突变蛋白连接的白细胞介素-4（IL-4）突变蛋白的嵌合多肽拮抗剂，编码IL-4和IL9嵌合突变蛋白拮抗剂的多核苷酸也是如此。还提供了使用嵌合突变蛋白拮抗剂并编码多肽以降低或抑制细胞对诸如IL-4，IL-9和/或白细胞介素-13的细胞因子的反应性的方法。还提供了使用组合物治疗诸如肺部疾病（例如哮喘）等病症的方法。

8. 发明申请

WO2004103295A2 INTERLEUKIN-9 ANTAGONIST MUTEINS AND THEIR PHARMACOLOGICAL METHODS OF USE 审中-公开
标题翻译：白细胞介素-9拮抗剂及其药理学方法
公开(公告)号：WO2004103295A2
公开(公告)日：2004-12-02
申请号：PCT/US2004015168
申请日：2004-05-14
申请人： BAYER PHARMACEUTICALS CORP , BOISVERT DAVID C , LONGPHRE MALINDA , ZAREMBA SYDNEY MORGAN , SHANAFELT ARMEN B
发明人： BOISVERT DAVID C , LONGPHRE MALINDA , ZAREMBA SYDNEY MORGAN , SHANAFELT ARMEN B
IPC分类号： A61K20060101 , A61K38/20 , C07K14/54 , A61K
CPC分类号： C07K14/5425
摘要： This invention relates to IL-9 muteins that inhibit the activity of wild-type IL-9, multimers and Fc-fusion constructs of IL-9 proteins, and an efficient method to purify IL-9 proteins produced by eukaryotic cells. Related formulations, dosages and methods of administration thereof for therapeutic purposes are also provided. More particularly, these IL-9 muteins, compositions, and methods provide a treatment option for individuals afflicted with conditions where inhibiting IL-9 mediated immune responses would be beneficial, such as allergy, asthma, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), pulmonary and gastro-intestinal mucus hyperplasia, inflammation, immunological disorders, leukemia, and lymphoma.
摘要翻译：本发明涉及抑制野生型IL-9，IL-9蛋白的多聚体和Fc融合构建体的活性的IL-9突变蛋白，以及用于纯化真核细胞产生的IL-9蛋白的有效方法。还提供了用于治疗目的的相关制剂，剂量和施用方法。更具体地说，这些IL-9突变蛋白，组合物和方法为抑制IL-9介导的免疫应答是有益的疾病（例如过敏，哮喘，慢性阻塞性肺病（肺气肿和慢性支气管炎））的患者提供治疗选择，，肺和胃肠粘液增生，炎症，免疫学障碍，白血病和淋巴瘤。

9. 发明申请

WO2002095008A2 METHODS OF MODULATING SURFACTANT PRODUCTION 审中-公开
标题翻译：调节表面活性剂生产的方法
公开(公告)号：WO2002095008A2
公开(公告)日：2002-11-28
申请号：PCT/US2002/002728
申请日：2002-01-30
申请人： BAYER CORPORATION , MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
发明人： MASON, Robert, James , NEBEN, Steven , ECKART, Michael, R. , LONGPHRE, Malinda
IPC分类号： C12N
CPC分类号： C07K14/4702 , A61K38/00
摘要： The present invention provides methods for modulating surfactant production using SREBP/ADD-1 polypeptides, and agonists or antagonists that are capable of modulating SREBP/ADD-1 activity. More particularly, the present invention encompasses the use of SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
摘要翻译：本发明提供使用SREBP / ADD-1多肽以及能够调节SREBP / ADD-1活性的激动剂或拮抗剂来调节表面活性物质生成的方法。更具体地，本发明包括SREBP / ADD-1多肽或激动剂或拮抗剂多肽用于治疗疾病或临床状况的用途，其中表面活性剂生产与疾病或临床病症的原因或治疗相关，例如肺疾病包括成人/婴儿呼吸窘迫综合征，急性肺损伤，慢性阻塞性肺病（肺气肿和慢性支气管炎），哮喘，肺泡蛋白沉积和相关肺部疾病。本发明还包括含有SREBP / ADD-1多肽或激动剂或拮抗剂多肽的药物组合物，以及这些药物组合物用于治疗上述疾病或临床病症的用途。

10. 发明申请

WO02074907A3 METHODS OF MODULATING SURFACTANT PRODUCTION 审中-公开
标题翻译：调节表面活性剂生产的方法
公开(公告)号：WO02074907A3
公开(公告)日：2002-11-21
申请号：PCT/US0205134
申请日：2002-01-30
申请人： BAYER AG , MASON ROBERT JAMES , NEBEN STEVEN , ECKART MICHAEL R , LONGPHRE MALINDA
发明人： MASON ROBERT JAMES , NEBEN STEVEN , ECKART MICHAEL R , LONGPHRE MALINDA
IPC分类号： A61K38/00 , A61K48/00 , C12N9/10 , A01N43/04 , C07H21/04 , C07K1/00 , C12N1/20 , C12N5/00 , C12N15/00 , C12P21/06 , C12Q1/00
CPC分类号： C12N9/1029 , A61K38/00 , A61K48/00 , C12Y203/01085
摘要： The present invention provides methods of modulating surfactant production using FAS polypeptides, and agonists or antagonists that are capable of modulating FAS activity. More particularly, the present invention encompasses the use of FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
摘要翻译：本发明提供了使用FAS多肽和能够调节FAS活性的激动剂或拮抗剂调节表面活性剂产生的方法。更特别地，本发明包括FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽用于治疗疾病或临床病症的用途，其中表面活性剂产生与疾病或临床病症的因果关系或治疗相关，如肺部疾病，包括成人/婴儿呼吸窘迫综合征，急性肺损伤，慢性阻塞性肺病（肺气肿和慢性支气管炎），哮喘，肺泡蛋白沉积症，小气道疾病和保持呼吸道通畅以及相关的肺部疾病。本发明还包括含有FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽的药物组合物，以及这些药物组合物用于治疗上述疾病或临床症状的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式